The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs

References

• Overdose Death Rates [Internet]. Bethesda (MD): National Institute on Drug Abuse; [updated on 2019; cited 2019 Jan 22]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates.
   Google Scholar
• Scholl L, Seth P, Kariisa M, et al. Drug and opioid-involved overdose deaths – United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018;67:1419–1427.
   PubMed Web of Science ®Google Scholar
• O‘Donnell JK, Halpin J, Mattson CL, et al. Deaths involving fentanyl, fentanyl analogs, and U-47700-10 states, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66:1197–1202.
   PubMed Web of Science ®Google Scholar
• Denton JS, Donoghue ER, McReynolds J, et al. An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007. J Forensic Sci. 2008;53:452–454.
   PubMed Web of Science ®Google Scholar
• Schumann H, Erickson T, Thompson TM, et al. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol (Phila). 2008;46:501–506.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Nonpharmaceutical fentanyl-related deaths – multiple states, April 2005–March 2007. MMWR Morb Mortal Wkly Rep. 2008;57:793–796.
   PubMedGoogle Scholar
• Drug Enforcement Administration (US). 2017 National drug threat assessment. Washington (DC): Department of Justice (US); 2017.
   Google Scholar
• Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addic Med. 2014;8:153–163.
   PubMed Web of Science ®Google Scholar
• Somerville NJ. Characteristics of fentanyl overdose – Massachusetts, 2014–2016. MMWR Morb Mortal Wkly Rep. 2017;66:382–386.
   PubMed Web of Science ®Google Scholar
• Sutter ME, Gerona RR, Davis MT, et al. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017;24:106–113.
   PubMed Web of Science ®Google Scholar
• Zuckerman M, Weisberg SN, Boyer EW. Pitfalls of intranasal naloxone. Prehosp Emerg Care. 2014;18:550–554.
   PubMed Web of Science ®Google Scholar
• Faul M, Lurie P, Kinsman JM, et al. Multiple naloxone administrations among emergency medical service providers is increasing. Prehosp Emerg Care. 2017;21:411–419.
   PubMed Web of Science ®Google Scholar
• Klebacher R, Harris MI, Ariyaprakai N, et al. Incidence of naloxone redosing in the age of the new opioid epidemic. Prehosp Emerg Care. 2017;166:1–6.
   Google Scholar
• Bell A, Bennett AS, Jones TS, et al. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Subst Abus. 2018;64:1–4.
   Google Scholar
• Stanley TH. The fentanyl story. J Pain. 2014;15:1215–1226.
   PubMed Web of Science ®Google Scholar
• Stanley TH, Egan TD, Van Aken H. A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesth Analg. 2008;106:451–462.
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Helander A, Garg U, et al. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union. Clin Chem. 2019;65:242–253.
   PubMed Web of Science ®Google Scholar
• Stanley TH. The history and development of the fentanyl series. J Pain Symptom Manage. 1992;7:S3–S7.
   PubMed Web of Science ®Google Scholar
• Ward CF, Ward GC, Saidman LJ. Drug abuse in anesthesia training programs. A survey: 1970 through 1980. JAMA. 1983;250:922–925.
   PubMed Web of Science ®Google Scholar
• Rosenberg M. Drug abuse in oral and maxillofacial training programs. J Oral Maxillofac Surg. 1986;44:458–462.
   PubMed Web of Science ®Google Scholar
• Bryson EO, Silverstein JH. Addiction and substance abuse in anesthesiology. Anesthesiology. 2008;109:905–917.
   PubMed Web of Science ®Google Scholar
• Kramer C, Tawney M. A fatal overdose of transdermally administered fentanyl. J Am Osteopath Assoc. 1998;98:385–386.
   PubMedGoogle Scholar
• Krinsky CS, Lathrop SL, Crossey M, et al. A toxicology-based review of fentanyl-related deaths in New Mexico (1986-2007). Am J Forensic Med Pathol. 2011;32:347–351.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (US). National Estimates of Drug-Related Emergency Department Visits, 2004-2011 - All Misuse and Abuse. Rockville (MD): Department of Health and Human Services (US); 2013. (HHS Publication No. (SMA) 13-4760, DAWN Series D-39).
   Google Scholar
• Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5:230–241.
   PubMedGoogle Scholar
• Flannagan LM, Butts JD, Anderson WH. Fentanyl patches left on dead bodies – potential source of drug for abusers. J Forensic Sci. 1996;41:320–321.
   PubMed Web of Science ®Google Scholar
• Coon TP, Miller M, Kaylor D, et al. Rectal insertion of fentanyl patches: a new route of toxicity. Ann Emerg Med. 2005;46:473.
   PubMed Web of Science ®Google Scholar
• Henderson GL. Blood concentrations of fentanyl and its analogs in overdose victims. Proc West Pharmacol Soc. 1983;26:287–290.
   PubMedGoogle Scholar
• Henderson GL. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J Forensic Sci. 1991;36:422–433.
   PubMed Web of Science ®Google Scholar
• Hibbs J, Perper J, Winek CL. An outbreak of designer drug-related deaths in Pennsylvania. JAMA. 1991;265:1011–1013.
   PubMed Web of Science ®Google Scholar
• Martin M, Hecker J, Clark R, et al. China white epidemic: an eastern United States emergency department experience. Acad Emerg Med. 1991;20:158–164.
   Google Scholar
• Smialek JE, Levine B, Chin L, et al. A fentanyl epidemic in Maryland 1992. J Forensic Sci. 1994;39:159–164.
   PubMed Web of Science ®Google Scholar
• Diversion Control Division (US). National forensic laboratory information system brief: fentanyl, 2001–2015. Springfield (VA): Drug Enforcement Administration (US); 2017.
   Google Scholar
• US Department of Justice, Drug Enforcement Administration. Control of a chemical precursor used in the illicit manufacture of fentanyl as a list I chemical. Fed Regist. 2007;72:20039–20047.
   PubMedGoogle Scholar
• Diversion Control Division (US). National forensic laboratory information system: NFLIS-drug 2017 annual report. Springfield (VA): Department of Justice, Drug Enforcement Administration (US); 2018.
   Google Scholar
• Frank RG, Pollack HA. Addressing the fentanyl threat to public health. N Engl J Med. 2017;376:605–607.
   PubMed Web of Science ®Google Scholar
• Vo KT, van Wijk XM, Lynch KL, et al. Counterfeit norco poisoning outbreak – San Francisco bay area, California, March 25–April 5, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:420–423.
   PubMed Web of Science ®Google Scholar
• Edison L, Erickson A, Smith S, et al. Notes from the field: counterfeit percocet-related overdose cluster – Georgia, June 2017. MMWR Morb Mortal Wkly Rep. 2017;66:1119–1120.
   PubMed Web of Science ®Google Scholar
• Arens AM, van Wijk XM, Vo KT, et al. Adverse effects from counterfeit alprazolam tablets. JAMA Intern Med. 2016;176:1554–1555.
   PubMed Web of Science ®Google Scholar
• Griswold MK, Chai PR, Krotulski AJ, et al. Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose. Clin Toxicol (Phila). 2018;56:37–42.
   PubMed Web of Science ®Google Scholar
• Kenney SR, Anderson BJ, Conti MT, et al. Expected and actual fentanyl exposure among persons seeking opioid withdrawal management. J Subst Abuse Treat. 2018;86:65–69.
   PubMed Web of Science ®Google Scholar
• Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11:S133–S153.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 2007;47:343–350.
   PubMed Web of Science ®Google Scholar
• Accessdata.fda.gov [Internet]. Silver Spring (MD): Duragesic: highlights of prescribing information; [cited 2019 Feb 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019813s069lbl.pdf
   Google Scholar
• Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59:385–390.
   PubMed Web of Science ®Google Scholar
• Anton B, Salazar A, Flores A, et al. Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin. 2009;5:214–229.
   PubMed Web of Science ®Google Scholar
• Tenore PL. Advanced urine toxicology testing. J Addict Dis. 2010;29:436–448.
   PubMed Web of Science ®Google Scholar
• Ruangyuttikarn W, Law MY, Rollins DE, et al. Detection of fentanyl and its analogs by enzyme-linked immunosorbent assay. J Anal Toxicol. 1990;14:160–164.
   PubMed Web of Science ®Google Scholar
• Expert Committee on Drug Dependence (CH). Carfentanil: critical review report - agenda item 4.8. Geneva (CH): World Health Organization (CH); 2017.
   Google Scholar
• Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med. 2017;11:256–265.
   PubMed Web of Science ®Google Scholar
• Publications Office of the European Union (EU). Carfentanil: EMCDDA- Europol Joint Report on a new psychoactive subtance: methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil). Luxembourg (EU): European Monitoring Centre for Drugs and Drug Addiction (EU); 2017.
   Google Scholar
• Feasel MG, Wohlfarth A, Nilles JM, et al. Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. Aaps J. 2016;18:1489–1499.
   PubMed Web of Science ®Google Scholar
• Concheiro M, Chesser R, Pardi J, et al. Postmortem toxicology of new synthetic opioids. Front Pharmacol. 2018;9:1210.
   PubMed Web of Science ®Google Scholar
• Minkowski CP, Epstein D, Frost JJ, et al. Differential response to IV carfentanil in chronic cocaine users and healthy controls. Addict Biol. 2012;17:149–155.
   PubMed Web of Science ®Google Scholar
• Seither J, Reidy L. Confirmation of carfentanil, U-47700 and other synthetic opioids in a human performance case by LC–MS-MS. J Anal Toxicol. 2017;41:493–497.
   PubMed Web of Science ®Google Scholar
• Swanson DM, Hair LS, Strauch Rivers SR, et al. Fatalities involving carfentanil and furanyl fentanyl: two case reports. J Anal Toxicol. 2017;41:498–502.
   PubMed Web of Science ®Google Scholar
• Acetyl fentanyl (N-N1-phenethylpiperidine-4-yl)-N-phenylacetamide) [Internet]. Springfield (VA): Department of Justice, Drug Enforcement Administration (US); 2018 [cited 2019 Feb 9]. Available from: https://www.deadiversion.usdoj.gov/drug_chem_info/acetylfentanyl.pdf
   Google Scholar
• Higashikawa Y, Suzuki S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. Forensic Toxicol. 2008;26:1–5.
   Web of Science ®Google Scholar
• Expert Committee on Drug Dependence (CH). Acetylfentanyl: critical review report – agenda item 5.2. Geneva (CH): World Health Organization (CH); 2015.
   Google Scholar
• Melent’ev AB, Kataev SS, Dvorskaya ON. Identification and analytical properties of acetyl fentanyl metabolites. J Anal Chem. 2015;70:240–248.
   Web of Science ®Google Scholar
• Armenian P, Vo KT, Barr-Walker J, et al. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134:121–132.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Vikingsson S, Roman M, et al. In vitro and in vivo metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl. Aaps J. 2017;19:1102–1122.
   PubMed Web of Science ®Google Scholar
• Diversion Control Division (US). NFLIS brief: fentanyl and fentanyl-related substances reported in NFLIS, 2015–2016. Spring Field (VA): Drug Enforcement Administration (US); 2017.
   Google Scholar
• Expert Committee on Drug Dependence (CH). Butyrfentanyl (Butyrylfentanyl) Critical review report – agenda item 4.2. Geneva (CH): World Healht Organization (CH); 2016.
   Google Scholar
• Alburges ME, Hanson GR, Gibb JW, et al. Fentanyl receptor assay. II. Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine. J Anal Toxicol. 1992;16:36–41.
   PubMed Web of Science ®Google Scholar
• Cole JB, Dunbar JF, McIntire SA, et al. Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage. Pediatrics. 2015;135:e740–e743.
   PubMed Web of Science ®Google Scholar
• Steuer AE, Williner E, Staeheli SN, et al. Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal. 2017;9:1085–1092.
   PubMed Web of Science ®Google Scholar
• Huang BS, Terrell RC, Deutsche KH, et al. The BOC Group Inc. N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds. United States patent US 4,584,303. 1986 April 22.
   Google Scholar
• Expert Committee on Drug Dependence (CH). Furanyl fentanyl Critical review report - agenda item 4.6. Geneva (CH): World Health Organization (CH); 2017.
   Google Scholar
• Mohr AL, Friscia M, Papsun D, et al. Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC-MS/MS in postmortem casework. J Anal Toxicol. 2016;40:709–717.
   PubMed Web of Science ®Google Scholar
• Rambaran KA, Amin ZM, Fleming SW, et al. AH-7921: a review of previously published reports. Proc (Bayl Univ Med Cent). 2018;31:303–306.
   Google Scholar
• Wohlfarth A, Scheidweiler KB, Pang S, et al. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. Drug Test Anal. 2016;8:779–791.
   PubMed Web of Science ®Google Scholar
• Brittain RT, Kellett DN, Neat ML, et al. Proceedings: anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides. Br J Pharmacol. 1973;49:158P–159P.
   PubMed Web of Science ®Google Scholar
• Harper NJ, Veitch GB, Wibberley DG. 1-(3,4-dichlorobenzamidomethyl)cyclohexyldimethylamine and related compounds as potential analgesics. J Med Chem. 1974;17:1188–1193.
   PubMed Web of Science ®Google Scholar
• Expert Committee on Drug Dependence (CH). AH-7921 critical review report – agenda item 4.21. Geneva (CH): World Health Organization (CH); 2014.
   Google Scholar
• Office of Diversion Control (US). National forensic laboratory information system special report: opiates and related drugs reported in NFLIS, 2009 through 2014. Spring Field (VA): Drug Enforcement Administration (US); 2015.
   Google Scholar
• Hayes AG, Tyers MB. Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol. 1983;79:731–736.
   PubMed Web of Science ®Google Scholar
• Expert Committee on Drug Dependence (CH). U-47700 critical review report –agenda item 4.1. Geneva (CH): World Health Organization (CH); 2016.
   Google Scholar
• Cheney BV, Szmuszkovicz J, Lahti RA, et al. Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor. J Med Chem. 1985;28:1853–1864.
   PubMed Web of Science ®Google Scholar
• Elliott SP, Brandt SD, Smith C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal. 2016;8:875–879.
   PubMedGoogle Scholar
• Drug Enforcement Administration, U.S. Department of Justice. Schedules of controlled substances: temporary placement of U-47700 into Schedule I. Final order. Fed Regist. 2016;81:79389–79393.
   PubMedGoogle Scholar
• Krotulski AJ, Mohr AL, Papsun DM, et al. Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users. Drug Test Anal. 2018;10:127–136.
   PubMed Web of Science ®Google Scholar
• Sharma KK, Hales TG, Rao VJ, et al. The search for the “next” euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning. Forensic Toxicol. 2019;37:1–16.
   PubMed Web of Science ®Google Scholar
• Krotulski AJ, Papsun DM, Friscia M, et al. Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. J Anal Toxicol. 2018;42:e27–e32.
   PubMed Web of Science ®Google Scholar
• McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids – conception and maturation. Drug Alcohol Depend. 2017;178:176–187.
   PubMed Web of Science ®Google Scholar
• Strang J, McDonald R, Alqurshi A, et al. Naloxone without the needle − systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend. 2016;163:16–23.
   PubMed Web of Science ®Google Scholar
• Walley AY, Doe-Simkins M, Quinn E, et al. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44:241–247.
   PubMed Web of Science ®Google Scholar
• Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
   PubMed Web of Science ®Google Scholar
• Edwards ET, Edwards ES, Davis E, et al. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther. 2015;4:1–17.
   PubMed Web of Science ®Google Scholar
• Ryan SA, Dunne RB. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain Manag. 2018;8:231–245.
   PubMed Web of Science ®Google Scholar
• Dowling J, Isbister GK, Kirkpatrick CM, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30:490–496.
   PubMed Web of Science ®Google Scholar
• Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6:20–31.
   PubMed Web of Science ®Google Scholar
• Kelly AM, Kerr D, Dietze P, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182:24–27.
   PubMed Web of Science ®Google Scholar
• Knopf A. Naloxone auto-injector gains FDA approval. Behav Healthc. 2014;34:48–49.
   PubMedGoogle Scholar
• Gupta G, Shah ND, Ross JS. The rising price of naloxone – risks to efforts to stem overdose deaths. N Engl J Med. 2016;375:2213–2215.
   PubMed Web of Science ®Google Scholar
• Elzey MJ, Fudin J, Edwards ES. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems. Expert Opin Drug Deliv. 2017;14:1045–1058.
   PubMed Web of Science ®Google Scholar
• Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29:265–271.
   PubMed Web of Science ®Google Scholar
• McDonald R, Lorch U, Woodward J, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study. Addiction. 2017;113:484–493.
   PubMed Web of Science ®Google Scholar
• Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14:1137–1146.
   PubMed Web of Science ®Google Scholar
• van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105:51–57.
   PubMed Web of Science ®Google Scholar
• Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9:63–88.
   PubMed Web of Science ®Google Scholar
• Neubig RR, Spedding M, Kenakin T, et al. International union of pharmacology committee on receptor nomenclature and drug classification. international union of pharmacology committee on receptor nomenclature and drug classification. XXXVIII. update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55:597–606.
   PubMed Web of Science ®Google Scholar
• Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226–238.
   PubMed Web of Science ®Google Scholar
• Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol. 2007;605:486–491.
   Web of Science ®Google Scholar
• Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther. 1989;45:66–71.
   PubMed Web of Science ®Google Scholar
• Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57:192–196.
   PubMed Web of Science ®Google Scholar
• Yassen A, Olofsen E, Romberg R, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther. 2007;81:50–58.
   PubMed Web of Science ®Google Scholar
• Green TC, Gilbert M. Counterfeit medications and fentanyl. JAMA Intern Med. 2016;176:1555–1557.
   PubMed Web of Science ®Google Scholar
• Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94:825–834.
   PubMed Web of Science ®Google Scholar
• Olofsen E, van Dorp E, Teppema L, et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology. 2010;112:1417–1427.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Sugiyama K, Hori M, et al. Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl. J Anesth. 2004;18:1–8.
   PubMedGoogle Scholar
• Uddayasankar U, Lee C, Oleschuk C, et al. The pharmacokinetics and pharmacodynamics of carfentanil after recreational exposure: a case report. Pharmacotherapy. 2018;38:e41–e45.
   PubMed Web of Science ®Google Scholar
• Moresco A, Larsen RS, Sleeman JM, et al. Use of naloxone to reverse carfentanil citrate-induced hypoxemia and cardiopulmonary depression in Rocky Mountain wapiti (Cervus elaphus nelsoni). J Zoo Wildl Med. 2001;32:81–89.
   PubMed Web of Science ®Google Scholar
• George AV, Lu JJ, Pisano MV, et al. Carfentanil – an ultra potent opioid. Am J Emerg Med. 2010;28:530–532.
   PubMed Web of Science ®Google Scholar
• Müller S, Nussbaumer S, Plitzko G, et al. Recreational use of carfentanil – a case report with laboratory confirmation. Clin Toxicol (Phila). 2018;56:151–152.
   PubMed Web of Science ®Google Scholar
• Cole JB, Nelson LS. Controversies and carfentanil: we have much to learn about the present state of opioid poisoning. Am J Emerg Med. 2017;35:1743–1745.
   PubMed Web of Science ®Google Scholar
• Willman MW, Liss DB, Schwarz ES, et al. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol. 2017;55:81–87.
   PubMed Web of Science ®Google Scholar
• Heaton JD, Bhandari B, Faryar KA, et al. Retrospective review of need for delayed naloxone or oxygen in emergency department patients receiving naloxone for heroin reversal. J Emerg Med. 2019 Apr 5:pii: S0736-4679(19)30121–0. [Epub ahead of print]. DOI: 10.1016/j.jemermed.2019.02.015
   PubMedGoogle Scholar
• Wheeler E, Jones TS, Gilbert MK, et al. Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:631–635.
   PubMed Web of Science ®Google Scholar
• Winstanley EL. Tangled-up and blue: releasing the regulatory chokehold on take-home naloxone. Addiction. 2016;111:583–584.
   PubMed Web of Science ®Google Scholar
• Wilkerson RG, Kim HK, Windsor TA, et al. The opioid epidemic in the United States. Emerg Med Clin North Am. 2016;32:e1–e23.
   Google Scholar
• Beletsky L, Ruthazer R, Macalino GE, et al. Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health. 2006;84:126–136.
   Web of Science ®Google Scholar
• Green TC, Zaller N, Palacios WR, et al. Law enforcement attitudes toward overdose prevention and response. Drug Alcohol Depend. 2013;133:677–684.
   PubMed Web of Science ®Google Scholar
• Tobin KE, Gaasch WR, Clarke C, et al. Attitudes of emergency medical service providers towards naloxone distribution programs. J Urban Health. 2005;82:296–302.
   PubMed Web of Science ®Google Scholar
• Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:1–8.
   PubMed Web of Science ®Google Scholar
• Publications Office of the European Union. (EU). Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone. Luxembourg (EU): European Monitoring Centre for Drugs and Drug Addiction (EU). 2015.
   Google Scholar
• Doyon S, Aks SE, Schaeffer S. Expanding access to naloxone in the United States. J Med Toxicol. 2014;10:431–434.
   PubMedGoogle Scholar
• Networkforphl.org [Internet]. Edina (MN): The Network for Public Health Law. Legal interventions to reduce overdose mortality: naloxone access and overdose Good Samaritan laws. [cited 2019 Feb 2]. Available from: https://www.networkforphl.org/_asset/qz5pvn/legal-interventions-to-reduce-overdose.pdf.
   Google Scholar
• Davis CS, Southwell JK, Niehaus VR, et al. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med. 2014;21:1173–1177.
   PubMed Web of Science ®Google Scholar
• Davis CS, Ruiz S, Glynn P, et al. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am J Public Health. 2014;104:e7–e9.
   PubMed Web of Science ®Google Scholar
• Office of National Drug Control Policy (US). National drug control strategy – 2010. Washington (DC): The White House (US); 2010.
   Google Scholar
• Lambdin BH, Zibbell J, Wheeler E, et al. Identifying gaps in the implementation of naloxone programs for laypersons in the United States. Int J Drug Policy. 2018;52::52–55.
   PubMed Web of Science ®Google Scholar
• Piper TM, Stancliff S, Rudenstine S, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse. 2008;43:858–870.
   PubMed Web of Science ®Google Scholar
• Mahonski S, Leonard JB, Gatz D, et al. North American Congress of Clinical Toxicology (NACCT) abstracts 2018-15. Bystander naloxone administration for undifferentiated opioid overdose in the era of non-pharmaceutical fentanyl: a retrospective study of a regional poison center data. Clin Toxicol (Phila). 2018;56:924.
   Web of Science ®Google Scholar
• Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111:1607–1613.
   PubMed Web of Science ®Google Scholar
• Mattson CL, O’Donnell J, Kariisa M, et al. Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 States, July 2016-June 2017. MMWR Morb Mortal Wkly Rep. 2018;67:945–951.
   PubMed Web of Science ®Google Scholar
• Stam NC, Gerostamoulos D, Smith K, et al. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia. Clin Toxicol (Phila). 2018;39:1–6.
   Google Scholar
• Levy B, Spelke B, Paulozzi LJ, et al. Recognition and response to opioid overdose deaths – New Mexico, 2012. Drug Alcohol Depend. 2016;167:29–35.
   PubMed Web of Science ®Google Scholar
• Riches JR, Read RW, Black RM, et al. Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use. J Anal Toxicol. 2012;36:647–656.
   PubMed Web of Science ®Google Scholar
• Van Nimmen NF, Poels KL, Veulemans HA. Identification of exposure pathways for opioid narcotic analgesics in pharmaceutical production workers. Ann Occup Hyg. 2006;50:665–677.
   PubMed Web of Science ®Google Scholar
• Roy SD, Flynn GL. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm Res. 1990;7:842–847.
   PubMed Web of Science ®Google Scholar
• Gourlay GK, Coulthard K. The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone. Br J Clin Pharmacol. 2006;15:269–271.
   Google Scholar
• DEA: DEA Warning to police and public: fentanyl exposure kills [Internet]. Springfield (VA): Drug Enforcement Administration; 2016 June 10 [cited 2019 Jan 26]; [3 screens]. Available from: https://www.dea.gov/divisions/hq/2016/hq061016.shtml
   Google Scholar
• CDC: Fentanyl: preventing occupational exposure to emergency responders [Internet]. Atlanta (GA): Center for Disease Control and Prevention; 2017 Aug 24 [cited 2019 Jan 29]. Available from: https://www.cdc.gov/niosh/topics/fentanyl/risk.html
   Google Scholar
• Moss MJ, Warrick BJ, Nelson LS, et al. ACMT and AACT position statement: preventing occupational fentanyl and fentanyl analog exposure to emergency responders. J Med Toxicol. 2017;13:347–351.
   PubMed Web of Science ®Google Scholar
• Kaleo Inc. Authorized Generic for EVZIO® (naloxone HCl injection) to be Available at a Reduced List Price of $178. 2018 Dec. Available from: https://kaleo.com/in-the-news/authorized-generic-for-evzio-naloxone-hcl-injection-to-be-available-at-a-reduced-list-price-of-178/.
   Google Scholar